ALFA Finder
India's fastest NSE & BSE filing alerts on Telegram, filtered to the stocks you hold
Telegram alerts
alfafinder.com →
ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
18 announcements with these filters
Gennex Laboratories will hold a board meeting on November 14, 2026. The board will consider unaudited financial results for the quarter ended September 30, 2026.
Gennex Laboratories Ltd has filed its quarterly shareholding pattern for the period ended September 30, 2026, as required under SEBI regulations.
Gennex Laboratories announced the appointment of Mr. Dipankar Dasgupta as Independent Director, replacing Mr. Amudala Sreeramulu Nageswar Rao, effective October 1, 2026.
Gennex Laboratories Limited held its 41st electronic Annual General Meeting on September 30, 2026. Proceedings included the adoption of financial statements and appointment of company directors.
Subsidiary Deccan Remedies Ltd received approvals from the Drug Control Administration, Andhra Pradesh, to manufacture ten additional pharmaceutical products and test licences at its facility.
Gennex Laboratories Limited announced the closure of its register of members from September 23 to September 30, 2026. This is for the upcoming 41st Annual General Meeting.
Gennex Laboratories announced the outcome of its board meeting, approving the draft directors' report and scheduling the 41st Annual General Meeting for September 30, 2026.
Gennex Laboratories has announced a board meeting scheduled for September 4, 2026, to discuss the upcoming 41st Annual General Meeting and other business matters.
Gennex Laboratories Ltd reported revenue from operations of ₹39.8 Cr (+16.4% YoY) and net profit of ₹4.7 Cr (-6.0% YoY) for Q1 FY27.
Gennex Laboratories scheduled a board meeting for August 14, 2026. The board will review unaudited financial statements for the June 30, 2026 quarter.
Gennex Laboratories Ltd filed its quarterly shareholding pattern. The company has applied for trading approval for 1.55 crore shares issued via warrant conversion.
Promoter Premier Fiscal Services pledged 25,00,000 shares for a Rs.1.25 Crore business loan. This increases promoter leverage and may signal financial stress.
Gennex Laboratories Ltd reported revenue from operations of ₹61 Cr (+51.4% YoY) and net profit of ₹4.5 Cr (+45.2% YoY) for Q4 FY26.
Gennex Laboratories reported a consolidated total income of ₹180.99 Crore for FY26. The Board approved audited results despite a qualified opinion regarding unconfirmed asset and liability balances.
Gennex Laboratories submitted its Annual Secretarial Compliance Report for the financial year 2025-26. The report confirms adherence to statutory regulations and outlines historical compliance actions taken.
Gennex Laboratories clarified that recent stock price movements are driven by external market factors. The company confirmed no undisclosed price-sensitive information exists.
Gennex Laboratories scheduled a board meeting for May 30, 2026, to approve audited financial results. The trading window remains closed until 48 hours post-declaration.
Gennex Laboratories Limited shareholders approved all EGM resolutions, including director regularization, with requisite majority. Results and scrutinizer's report for the May 12 meeting are enclosed.